Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | ADH1B | P00325 | 1/20 | 0.38 |
| ▸ | ADH1C | P00326 | 1/20 | 0.38 |
| ▸ | ADH1A | P07327 | 1/20 | 0.38 |
| ▸ | ADH4 | P08319 | 1/20 | 0.38 |
| ▸ | ADH7 | P40394 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3514243 | 0.97 | EPHX1 (0.45) | EPHX1HPGDKMT2AEPHX2ALOX5 | |
| SCHEMBL1148328 | 0.87 | EPHX1 (0.54) | EPHX1HPGDKMT2AEPHX2ALOX5 | |
| SCHEMBL7945281 | 0.87 | EPHX1 (0.54) | EPHX1HPGDKMT2AEPHX2ALOX5 | |
| SCHEMBL3116167 | 0.84 | EPHX1 (0.50) | EPHX1HPGDKMT2AEPHX2ALOX5 | |
| SCHEMBL11974545 | 0.82 | EPHX1 (0.56) | EPHX1HPGDKMT2AEPHX2ALOX5 | |
| SCHEMBL791953 | 0.81 | EPHX1 (0.41) | EPHX1HPGDKMT2AEPHX2 | |
| SCHEMBL9298439 | 0.79 | EPHX1 (0.52) | EPHX1HPGDKMT2AEPHX2ALOX5 | |
| SCHEMBL3855877 | 0.78 | KMT2A (0.44) | EPHX1HPGDKMT2AEPHX2ALOX5 | |
| SCHEMBL2789911 | 0.78 | EPHX1 (0.47) | EPHX1HPGDKMT2AEPHX2ALOX5 | |
| SCHEMBL8397024 | 0.78 | EPHX1 (0.47) | EPHX1HPGDKMT2AEPHX2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3817575-B1 | SOLUBILISATION OF COOLING AGENTS OF LOW SOLUBILITY | SYMRISE AG (DE) | 2025-10-15 | — | — | EP | claimed |
| US-20250163006-A1 | New Coolants, and Preparations Containing Same | SYMRISE AG (DE) | 2025-05-22 | — | — | US | claimed |
| US-20250066320-A1 | Active Ingredients with Sialagogue and Tingling/Fizzy Effect, and Preparations Containing Same | SYMRISE AG (DE) | 2025-02-27 | — | — | US | claimed |
| WO-2025026525-A1 | HETEROCYCLIC COMPOUNDS AS PHYSIOLOGICAL COOLANTS | SYMRISE AG (DE) | 2025-02-06 | — | — | WO | claimed |
| EP-4469439-A1 | NEW COOLANTS, AND PREPARATIONS CONTAINING SAME | Symrise AG (DE) | 2024-12-04 | — | — | EP | claimed |
| EP-4452941-A1 | ACTIVE INGREDIENTS WITH SIALAGOGUE AND TINGLING/FIZZY EFFECT, AND PREPARATIONS CONTAINING SAME | Symrise AG (DE) | 2024-10-30 | — | — | EP | claimed |
| US-20240000746-A1 | New Cooling Agents and Preparations Containing Them | SYMRISE AG (DE) | 2024-01-04 | — | — | US | claimed |
| EP-4247791-A2 | NEW COOLANTS, AND PREPARATIONS CONTAINING SAME | Symrise AG (DE) | 2023-09-27 | — | — | EP | claimed |
| WO-2023144326-A1 | NEW COOLANTS, AND PREPARATIONS CONTAINING SAME | SYMRISE AG (DE) | 2023-08-03 | — | — | WO | claimed |
| WO-2023143741-A1 | NEW COOLANTS, AND PREPARATIONS CONTAINING SAME | SYMRISE AG (DE) | 2023-08-03 | — | — | WO | claimed |
| WO-2023117119-A1 | ACTIVE INGREDIENTS WITH SIALAGOGUE AND TINGLING/FIZZY EFFECT, AND PREPARATIONS CONTAINING SAME | SYMRISE AG (DE) | 2023-06-29 | — | — | WO | claimed |
| WO-2022105986-A1 | NOVEL COOLING AGENTS AND PREPARATIONS CONTAINING SAME | SYMRISE AG (DE) | 2022-05-27 | — | — | WO | claimed |
| WO-2022106452-A2 | NEW COOLANTS, AND PREPARATIONS CONTAINING SAME | SYMRISE AG (DE) | 2022-05-27 | — | — | WO | claimed |
| EP-3817575-A1 | SOLUBILIZATION OF POORLY SOLUBLE COOLING SUBSTANCES | Symrise AG (DE) | 2021-05-12 | — | — | EP | claimed |
| CN-112384077-A | Solubilization of poorly soluble cooling substances | 西姆莱斯有限公司 | 2021-02-19 | — | — | CN | claimed |
| WO-2020007484-A1 | SOLUBILIZATION OF POORLY SOLUBLE COOLING SUBSTANCES | SYMRISE AG (DE) | 2020-01-09 | — | — | WO | claimed |
| EP-3817575-B1 | SOLUBILISATION OF COOLING AGENTS OF LOW SOLUBILITY | SYMRISE AG (DE) | 2025-10-15 | — | — | EP | disclosed |
| US-12440435-B2 | Solubilization of poorly soluble cooling substances | SYMRISE AG (DE) | 2025-10-14 | — | — | US | disclosed |
| WO-2008051405-A1 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008051405-A1 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066320-A1 | Active Ingredients with Sialagogue and Tingling/Fizzy Effect, and Preparations Containing Same | TAS2R5, TAS2R7, TAS2R8 | EPHX1 2617/4885HPGD 428/4885KMT2A 2748/4885 |
| US-20240000746-A1 | New Cooling Agents and Preparations Containing Them | TTPA, TREH, TAS2R45 | EPHX1 1993/4885HPGD 1155/4885KMT2A 4030/4885 |
| US-20250163006-A1 | New Coolants, and Preparations Containing Same | TTR, TAS2R5, TAS2R50 | EPHX1 2081/4885HPGD 1963/4885KMT2A 3992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.